EA200900291A1 - МОДУЛЯТОРЫ РЕЦЕПТОРА ГЛЮКОКОРТИКОИДОВ И/ИЛИ АР-1, И/ИЛИ NF-kB И ИХ ПРИМЕНЕНИЕ - Google Patents

МОДУЛЯТОРЫ РЕЦЕПТОРА ГЛЮКОКОРТИКОИДОВ И/ИЛИ АР-1, И/ИЛИ NF-kB И ИХ ПРИМЕНЕНИЕ

Info

Publication number
EA200900291A1
EA200900291A1 EA200900291A EA200900291A EA200900291A1 EA 200900291 A1 EA200900291 A1 EA 200900291A1 EA 200900291 A EA200900291 A EA 200900291A EA 200900291 A EA200900291 A EA 200900291A EA 200900291 A1 EA200900291 A1 EA 200900291A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ring
diseases
different
substituted
salkenylene
Prior art date
Application number
EA200900291A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид С. Вэйнштейн
Хуа Гонг
Джинву Дуан
Т.Г. Мурали Дар
Бинвэй Вера Ян
Пин Чэнь
Бинь Цзян
Артур М.П. Довейко
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA200900291A1 publication Critical patent/EA200900291A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA200900291A 2006-08-09 2007-08-09 МОДУЛЯТОРЫ РЕЦЕПТОРА ГЛЮКОКОРТИКОИДОВ И/ИЛИ АР-1, И/ИЛИ NF-kB И ИХ ПРИМЕНЕНИЕ EA200900291A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83649606P 2006-08-09 2006-08-09
US11/835,438 US8034940B2 (en) 2006-08-09 2007-08-08 Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
PCT/US2007/075543 WO2008021926A2 (en) 2006-08-09 2007-08-09 Modulators of glucocorticoid receptor, and/or ap-1, and/or nf-kb activity and use thereof

Publications (1)

Publication Number Publication Date
EA200900291A1 true EA200900291A1 (ru) 2009-10-30

Family

ID=39052386

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900291A EA200900291A1 (ru) 2006-08-09 2007-08-09 МОДУЛЯТОРЫ РЕЦЕПТОРА ГЛЮКОКОРТИКОИДОВ И/ИЛИ АР-1, И/ИЛИ NF-kB И ИХ ПРИМЕНЕНИЕ

Country Status (17)

Country Link
US (1) US8034940B2 (enExample)
EP (1) EP2049507A2 (enExample)
JP (1) JP2010500376A (enExample)
KR (1) KR20090038930A (enExample)
CN (1) CN101528718B (enExample)
AR (1) AR062312A1 (enExample)
AU (1) AU2007286221A1 (enExample)
BR (1) BRPI0716641A2 (enExample)
CA (1) CA2660318A1 (enExample)
CL (1) CL2007002330A1 (enExample)
EA (1) EA200900291A1 (enExample)
IL (1) IL196814A0 (enExample)
MX (1) MX2009001220A (enExample)
NO (1) NO20090564L (enExample)
PE (1) PE20081314A1 (enExample)
TW (1) TW200815454A (enExample)
WO (1) WO2008021926A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067447B2 (en) 2006-11-01 2011-11-29 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP2099767A1 (en) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
ATE550337T1 (de) 2006-11-01 2012-04-15 Bristol Myers Squibb Co Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kappa-b-aktivität und deren verwendung
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2009100171A1 (en) * 2008-02-07 2009-08-13 Bristol-Myers Squibb Company Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof
EP2282742A1 (en) * 2008-04-09 2011-02-16 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8791258B2 (en) * 2008-06-10 2014-07-29 The Regents Of The University Of California Pro-fluorescent probes
EP2334671A1 (en) * 2008-06-24 2011-06-22 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
WO2010001990A1 (ja) 2008-07-03 2010-01-07 協和発酵キリン株式会社 四環系化合物
WO2011081173A1 (ja) * 2009-12-29 2011-07-07 協和発酵キリン株式会社 四環系化合物
US9845512B2 (en) * 2010-01-15 2017-12-19 Rigel Pharmaceuticals, Inc. Screening assay employing Dex and GDF8
US9796720B2 (en) 2013-08-22 2017-10-24 Bristol-Myers Squibb Company Imidazole-derived modulators of the glucocorticoid receptor
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
US20180030065A1 (en) * 2015-01-27 2018-02-01 Isi Life Sciences, Inc. Fluorescein polymer conjugates
WO2018030550A1 (en) 2016-08-09 2018-02-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds with an ror(gamma)t modulating activity
EP3735410A4 (en) * 2017-10-19 2021-11-03 Tempest Therapeutics, Inc. PICOLINAMIDE COMPOUNDS
CN113862704B (zh) * 2021-11-15 2023-07-21 南昌航空大学 一种9-芳基呫吨类化合物的制备方法
AR127618A1 (es) 2021-11-29 2024-02-14 Bayer Ag Dihidropiranopiridinas sustituidas, sales o n-óxidos de las mismas y su uso como sustancias herbicidamente activas
CN117105821A (zh) * 2023-04-18 2023-11-24 重庆普佑制药有限公司 一种沙库比曲中间体的制备方法
CN117105820A (zh) * 2023-07-12 2023-11-24 上海阿拉丁生化科技股份有限公司 一种4-氟苯乙基异氰酸酯的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5053414A (en) 1988-04-08 1991-10-01 Ono Pharmaceutical Co., Ltd. Heterocyclic compounds
US5073566A (en) 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
CZ282084B6 (cs) 1991-09-13 1997-05-14 Sankyo Company Limited Tricyklické heterocyklické sloučeniny, způsob výr oby a farmaceutické prostředky s jejich obsahem
US5453421A (en) 1992-09-11 1995-09-26 E. R. Squibb & Sons, Inc. Aryl and heterocyclic substituted propenamide derivatives
TW306916B (enExample) 1994-09-13 1997-06-01 Ciba Geigy Ag
DE19610882A1 (de) 1996-03-20 1997-09-25 Dresden Arzneimittel Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU741839B2 (en) 1996-10-04 2001-12-13 Novo Nordisk A/S N-substituted azaheterocyclic compounds
JP2000510870A (ja) 1997-02-14 2000-08-22 バイエル・コーポレーシヨン Ｎｐｙ５受容体アンタゴニストとしてのアミド類
AR014195A1 (es) 1997-12-29 2001-02-07 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles para el tratamiento de procesos inflamatorios, composiciones anti-inflamatorias que los comprenden, ymetodos para prepararlos
KR20020014797A (ko) 1999-05-17 2002-02-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 글루카곤 길항제/역 아고니스트
PL373484A1 (en) 2001-12-10 2005-09-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2005066153A1 (en) 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
CN1918151A (zh) 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
WO2006053342A2 (en) 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP4943826B2 (ja) 2005-11-25 2012-05-30 田辺三菱製薬株式会社 医薬組成物
ATE550337T1 (de) 2006-11-01 2012-04-15 Bristol Myers Squibb Co Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kappa-b-aktivität und deren verwendung
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP2099767A1 (en) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
US8067447B2 (en) 2006-11-01 2011-11-29 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof

Also Published As

Publication number Publication date
AU2007286221A1 (en) 2008-02-21
JP2010500376A (ja) 2010-01-07
US20090075995A1 (en) 2009-03-19
WO2008021926A2 (en) 2008-02-21
WO2008021926A3 (en) 2008-05-22
US8034940B2 (en) 2011-10-11
BRPI0716641A2 (pt) 2013-10-15
TW200815454A (en) 2008-04-01
PE20081314A1 (es) 2008-10-17
IL196814A0 (en) 2009-11-18
KR20090038930A (ko) 2009-04-21
AR062312A1 (es) 2008-10-29
CL2007002330A1 (es) 2008-02-15
CN101528718A (zh) 2009-09-09
EP2049507A2 (en) 2009-04-22
CN101528718B (zh) 2011-11-09
CA2660318A1 (en) 2008-02-21
MX2009001220A (es) 2009-02-11
NO20090564L (no) 2009-03-19

Similar Documents

Publication Publication Date Title
EA200900291A1 (ru) МОДУЛЯТОРЫ РЕЦЕПТОРА ГЛЮКОКОРТИКОИДОВ И/ИЛИ АР-1, И/ИЛИ NF-kB И ИХ ПРИМЕНЕНИЕ
RU2495044C2 (ru) Ингибиторы активности протеинтирозинкиназы
EA201391639A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
EA201490287A1 (ru) Новые замещенные производные индола в качестве модуляторов гамма-секретазы
EA201270166A1 (ru) Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы
EA201171066A1 (ru) Новые замещенные производные бензоксазола, бензимидазола, оксазолопиридина и имидазопиридина в качестве модуляторов гамма-секретазы
EA201071329A1 (ru) Диамидные производные адамантана и их применение
EA201070143A1 (ru) Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
EA201071370A1 (ru) Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы
EA200870360A1 (ru) Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201690899A1 (ru) Оксазепины в качестве модуляторов ионных каналов
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
BR112012028445A2 (pt) compostos de heteroarila bicíclica como moduladores de gpr119
EA201291272A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
EA201070169A1 (ru) 2,3-дигидробензо[1,4]диоксин-2-илметиловые производные в качестве альфа2с антагонистов для применения в лечении заболеваний перифирической центральной нервной системы
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
EA202191968A1 (ru) Новые замещенные производные сульфонилмочевины